Ewing's sarcoma and extracranial primitive neuroectodermal tumors

Current Opinion in Oncology

Volumn 8, Issue 4, 1996, Pages 305-310

  Granowetter, Linda ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW RESCUE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL TRANSPLANTATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 22; CLINICAL FEATURE; CYTOGENETICS; EWING SARCOMA; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOCYTOCHEMISTRY; NEUROECTODERM TUMOR; PRIORITY JOURNAL; REVIEW;

EID: 0029784254     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199607000-00007     Document Type: Review

References (48)

1. Ewing J: Diffuse endothelioma of bone. Proc NY Pathol Soc 1921, 21:17.
2. Whang-Peng J, Triche TJ, Knutsen T: Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 1984, 311:584-585.
3. Turc-Carel C, Philp I, Berger MP: Chromosome translocation in Ewing's sarcoma. N Engl J Med 1983, 309:497-498.
4. McKeon C, Thiele CJ, Ross RA, et al.: Indistinguishable pattern of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma. Cancer Res 1988, 48:4307-4311.
5. Zucman J, Delattre O, Demaze C, et al.: Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosom Cancer 1992, 5:271-277.
6. Sorensen PHB, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT: A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nature Genet 1994, 6:146-151.
7. Dunn T, Praissman L, Hagag N, Viola M: ERG gene is translocated in an Ewing's sarcoma cell line. Cancer Genet Cytogenet 1994, 76:19-22.
8. Giovannini M, Biegel JA, Serra M, Wang J-Y, Wei YH, Nycum L, Emanuel BS, Evans GA: EWS-ERG and EWS-FLI1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest 1994, 94:489-496.
9. Zoubek A, Pfleiderer C, Salzer-Kuntschik M, Amann G, Windhager R, Fink FM, Koscielniak E, Delattre O, Strehl S, Ambros PF, Gadner H, Kovar H: Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. Br J Cancer 1994, 11:908-913.
10. Delattre O, Zucman J, Plougastel B, et al.: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumors. Nature 1992, 359:162-165.
11. Delattre O, Zucman J, Melot T, Garau XS, Zucker J, Lenoir M, Ambros PF, Sheer D, Turc-Carel C, Triche TJ, Aurias A, Thomas G: The Ewing family of tumors: a subgroup of small round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994, 331:294-299.
12. Pellin A, Boix J, Blesa JR, Noguera R, Carda C, Llombart-Bosch A: EWS/FLI-1 rearrangement in small round cell sarcomas of bone and soft tissue detected by reverse transcrlptase polymerase chain reaction amplification. Eur J Cancer 1994, 30:827-831.
13. Barr FG, Chatten J, D'Cruz CM, Wilson AE, Nauta LE, Nycum LM, Biegel JA, Womer RA: Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 1995, 273:553-557. Reverse transcriptase polymerase chain reaction for the EWS-FLI1 and EWS-ERG fusion transcripts and transcripts associated with rhabdomyosarcoma (PAX3-FKHR or PAX7-FKHR) and desmoplastic round cell tumors were applied to 79 soft tissue sarcoma samples and compared with histopathologic slides. Six of eight ES samples were positive for the ES transcript, and one of seven undifferentiated sarcomas was positive.
14. Downing JR, Khandekar A, Shurtleff SA, Head DR, Parham DM, Webber BL, Pappo AS, Hulshof MG, Conn WP, Shapiro DN: Multiplex RT-PCR assay for the differential diagnosis of alveolar rhabdomyosarcoma and Ewing's sarcoma. Am J Pathol 1995, 146:626-634. Multiplex RT-PCR for the EWS/FL/1 message associated with ES in combination with the PAX3/FKHR message associated with the t(2;13) translocation of alveolar rhabdomyosarcoma was used to develop a rapid test to identify either tumor in a biopsy sample. Forty-four pediatric sarcomas and eight cell lines were examined; zero of eight ES and undifferentiated sarcomas expressed the PAX message. The sensitivity of the assay for rhabdomyosarcoma with the t(2;13) translocation was excellent.
15. Dockhorn-Dworniczak B, Schafer K-L, Dantcheva R, Blasius S, Winkelmann W, Strehl S, Burdach S, van Valen F, Jürgens H, Bocker W: Diagnostic value of the molecular genetic detection of the t(11;22) translocation in Ewing's tumours. Virchows Archiv 1994, 425:107-112.
16. Jeon A, Davis NJ, Braun BS, Sublett JE, Roussel MF, Denny CT, Shapiro DN: A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995, 10:1229-1234.
17. Murray JC, Langston C, Dreyer ZE, Stephenson CT, Pokorny WJ, Horowitz ME, Cooley LD: Atypical cytogenetic aberrations in two childhood peripheral primitive neuroectodermal tumors. Genes Chromosome Cancer 1995, 12:142-147.
18. Hamilton G, Fellinger EJ, Schratter I, Fritsch A: Characterization of a human endocrine tissue and tumor associated Ewing's sarcoma antigen. Cancer Res 1988, 48:6127-6134.
19. Perlman EJ, Dickman PS, Askin FB, Grier HE, Miser JS, Link MP: Ewing's sarcoma: routine diagnostic utilization of MIC2 analysis. A Pediatric Oncology Group/Children's Cancer Study Group intergroup study. Hum Pathol 1994, 25:304-307.
20. MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 1994, 18:486-494.
21. Hijazi YM, Axiotis CA, Navarro S, Steinberg SM, Horowitz ME, Tsokos M: Immunohistochemical detection of p-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol 1994, 102:61-67.
22. Triche TJ: Multiple-drug resistance in Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Am J Clin Pathol 1994, 102:1-2.
23. Fisher R, Kaste SC, Parham DM, Shapiro DN, Pappo AS: Ewing's sarcoma as a second malignant tumor in a child previously treated for Wilms' tumor. J Pediatr Heamatol Oncol 1995, 17:76-80. Five years after the diagnosis and treatment of Wilm's tumor, a 10-year-old girl developed ES, arising from the ribs at the edge of a previously irradiated field.
24. Jimenez M, Leon P, Castro L, Azcona C, Sierrrasesumage L: Second tumors in pediatric oncologic patients: report of 5 h.cases Rev Med Univ Navarra 1995, 40:72-77. In a review of second malignant tumors after treatment of childhood cancer, a case of ES of the fibula after survival of neuroblastoma was noted.
25. Toresky JA, Neckers L, Wexler LH: Detection of (11;22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of patients with Ewing's sarcoma family of tumors. J Natl Cancer Inst 1995, 86:285-286. Granulocyte colony-stimulating factor-mobilized peripheral blood cells were collected for a period of 1 to 3 days after two to four cycles of myelosuppressive induction therapy from 11 previously treated patients with bulky tumors and five newly diagnosed patients (two with localized tumors, three with known metastases) who had negative bone marrow samples before collection. Using RT-PCR assays, 52 samples of peripheral blood, bone marrow, and peripheral blood progenitor cells were examined. Fifty-four percent (13 of 24) of the progenitor collections, 47% of the peripheral blood samples (eight of 17), and 50% (six of 12) of the bone marrow specimens were positive for the t(11;22) translocation.
26. Oberlin O, Bayle C, Hartmann O, Terrier-Lacombe MJ, Lemerle J: Incidence of bone marrow involvement in Ewing's sarcoma: value of extensive investigation of the bone marrow. Med Pediatr Oncol 1995, 24:343-346. Fifty-nine untreated patients and five relapsed ES patients whose condition relapsed underwent multiple-site bone marrow studies under general anesthesia. Standard slides were compared with cytocentrifuged pooled specimens; no difference could be proven based on technique. Sixty-nine percent of patients with bone metastases had positive bone marrow samples, and 30% of patients with lung metastases had positive bone marrow samples. Fever and pelvic site was highly correlated with marrow disease. There was some evidence of focality, but only one patient had marrow disease not discernible by biopsy.
27. Howman-Giles R, Uren RF, Kellie SJ: Gallium and thallium scintigraphy in pediatric peripheral neuroectodermal tumor (askin tumor) of the chest wall. J Nucl Med 1995, 6:814-816. In a case report, a child with a PNET of the chest wall underwent gallium-67 and thallium-201 scanning as part of diagnostic studies and follow up; The thallium scan was more sensitive than gallium in finding a biopsy-positive residual mass.
28. Schmidt D, Hermann C, Jurgens H, Hanns D: Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma: a report from the Kiel pediatrictumor registry. Cancer 1991, 68:2251-2259.
29. Hartman KR, Triche TJ, Miser JS: Prognostic value of histopathology in Ewing's sarcoma: long term follow-up of distal extremity primary tumors. Cancer 1991, 67:163-171.
30. Terrier Ph, Henry-Amar M, Triche TJ, Horowitz ME, Terrier-Lacombe M-J, Miser JS, Kinsella TJ, Contesso G, Llombart-Bosch AL: Is neuroectodermal differentiation of Ewing's sarcoma of bone associated with an unfavorable prognosis? Eur J Cancer 1995, 31A:307-314. The Institut Gustave Roussy, the University of Valencia Medical School, and the National Cancer Institute participated in a retrospective review of the pathology of 315 patients. Five pathologists classified tumors as typical ES (220), atypical ES (48), or ES with neuroectodermal features (47). Multivariate analysis, including histopathological classification, patient age, site, presence of metastases, and treatment ("modern" or "others") demonstrated that the presence of a filigree pattern and dark cells conferred poor prognosis: however, neuroectodermal features did not confer poor prognosis. Clinical factors associated with poor prognosis in the study were treatment, metastases at diagnosis, and proximal tumor location.
31. Hoffer FA, Gianturco LE, Fletcher JA, Grier HE: Percutaneous biopsy of peripheral primitive neuroectodermal tumors and Ewing's sarcomas for cytogenetic analysis. Am J Roent 1994, 162:1141-1142.
32. Scully SP, Temple HT, O'Keefe RJ, Scarborough MT, Mankin HJ, Gebhardt MC: Role of surgical resection in pelvic Ewing's sarcoma. J Clin Oncol 1995, 13:2336-2341. Retrospective evaluation of 39 patients with ES of the pelvis was undertaken. Twenty patients were treated with radiation only and 19 with surgery with or without radiation. Local radiation failed three patients in each group. Disease-free survival was not significantly different between patients who underwent surgery and those who did not (16 vs 22 months median disease-free interval). These patients were treated with a variety of regimens over a 16-year period; however, the time of treatment did not appear to effect the outcome.
33. Dunst J, Jurgens H, Sauer R, Hildegard P, Paulussen M, Winkelmann W, Rube C: Radiation therapy in Ewing's sarcoma: an update of the CESS 86 Trial. Int J Radiat Oncol Biol Phys 1995, 32:919-930. Analysis of the German cooperative ES trial conducted between 1986 and 1991 showed that among 177 patients with ES of bone treated on standardized chemotherapy, overall survival and relapse-free survival (69%) did not differ according to local control method. Although there was a better local control rate after radical surgery, there were also more metastases in this group. Patients were selected for local treatment regimen by clinical status and clinician preference.
34. Nesbit ME, Gehan EA, Burgert O, Vietti TJ, Cangir A, Tefft M, Evans R, Thomas P, Askin F, Kissane JM, Pritchard DJ, Hermann J, Neff J, Makley JT, Gilula T: Multimodal therapy for the management of primary nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol 1990, 8:1664-1674.
35. Burgert OE, Nesbitt ME, Garnsey LA, Gehan EA, Hermann J, Vietti TJ, Cangir A, Tefft M, Evans R, Thomas P, Askin F, Kissane JM, Pritchard DJ, Neff J, Makley JT, Gilula L: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990, 8:1514-1524.
36. Smith MA: The impact of doxorubicin dose intensity on survival of patients with Ewing's sarcoma. J Clin Oncol 1991, 9:889-891.
37. Grier H, Krailo M, Link M, Tarbell N, Fryer C, Pritchard D, Gebhardt M, Dickman P, Pearlman E, Meyer P, Moore S, Raussen A, Vietti T, Miser J: Improved outcome in non-metastatic Ewing's sarcoma (EWS) and PNET of bone with the addition of ifosfamide and etoposide to vincristine, adriamycin, cyclophosphamide, and actinomycin: a Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) report. Proc A SCO 1994, 13:421.
38. Dunst J, Sauer R, Burgers JVM, et al.: Radiation therapy as local treatment in Ewing's sarcoma: Results of the Cooperative Ewing's Sarcoma studies CESS 81 and 86. Cancer 1991, 67:2818-2825.
39. Cangir A, Vietti TJ, Gehan EA, Burgert OE, Thomas P, Tefft M, Nesbitt ME, Kissane J, Pritchard D: Ewing's sarcoma metastatic at diagnosis results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 66:887-893.
40. Burdach S, Jurgens H, Peters C, Nurnberger W, Mauz-Korholz C, Korholz D, Paulussen M, Pape H, Dilloo D, Koscielniak E, Gadner H, Gobel U: Myeloablative radiochemotherapy and hematopoietic stem cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993, 77:1482-1488.
41. Michon J, Hartmann O, Demeocq F, Brunat-Mentigny M, Coze C, Boutard P, Avet-Loiseau H, Plantaz D, Girault D, Goubet J, Oberlin O, Zucker JM: Consolidation with busulfan and melphalan followed by blood progenitor cell graft in children and young adults with high risk Ewing's sarcoma: a report of the French Society of Pediatric Oncology. Proc ASCO 1994, 13:414.
42. Ladenstein R, Lasset C, Pinkerton R, Zucker JM, Peters C, Burdach H, Pardo N, Allorso G, Coze C, Buclon M, Philip T, Hartmann O: Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995, 15:697-705. Fifty ES and 13 PNET patients in complete remission were treated with megatherapy and marrow or PSC rescue between 1982 and 1992. Thirty-two patients were in first complete remission and 31 in second complete remission. With a median follow-up of 4 years, patients in their first complete remission had a 21% 5-year survival; patients in their second complete remission had a 32% event-free survival.
43. Scorpio RJ, Stokes K, Grattan-Smith D, Tiedemann K: Percutaneous localization of small pulmonary metastases, enabling limited resection. J Pediatr Surg 1994, 29:685-687.
44. Heij HA, Vos AN, de Kraker J, Voute PA: Prognostic factors in surgery for pulmonary metastases in children. Surgery 1994, 115:687-693.
45. Temeck BK, Wexler LH, Steinberg SM, McCLure LL, Horowitz M, Pass HI: Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg 1995, 59:1385-1390. The National Cancer Institute experience with metastatectomy was reviewed. In regard to the 28 ES patients, the median survival after metastasectomy was 1.7 years.
46. Kinsella TJ, Miser JS, Waller B, Venzon D, Glatstein E, Weaver-McClure L, Horowitz ME Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy, Int J Radiat Oncol Biol 1991, 20:389-395.
47. Gasparini M, Lombardi F, Ballerini E, Gandola L, Gianni M, Massimino M, Rottoli L, Fossati-Bellani F: Long-term outcome of patients with monostotic Ewing's sarcoma treated with combined modality. Med Pediatr Oncol 1994, 23:406-412.
48. Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr: Letter to the editor: second cancers in patients with Ewing's sarcoma. Med Pediatr Oncol 1994, 22:296-297.